64993-07-3

Basic information

• Product Name: 6-NITRO-1,3-BENZODIOXOL-5-AMINE
• Synonyms: 5-Amino-6-nitro-1,3-benzodioxole;6-nitrobenzo[d][1,3]dioxol-5-amine
• CAS NO: 64993-07-3
• Molecular Formula: C₇H₆N₂O₄
• Molecular Weight: 182.14
• Mol File: 64993-07-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 370.7 °C at 760 mmHg
• Flash Point: 178 °C
• Appearance: /
• Density: 1.587 g/cm³
• Vapor Pressure: 1.09E-05mmHg at 25°C
• Refractive Index: 1.676
• CAS DataBase Reference: 6-NITRO-1,3-BENZODIOXOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-NITRO-1,3-BENZODIOXOL-5-AMINE(64993-07-3)
• EPA Substance Registry System: 6-NITRO-1,3-BENZODIOXOL-5-AMINE(64993-07-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 64993-07-3(Hazardous Substances Data)

Usage

General Description

6-NITRO-1,3-BENZODIOXOL-5-AMINE is a chemical compound with the molecular formula C8H6N2O4. It is a nitroamine derivative of 1,3-benzodioxole and is commonly used in the synthesis of pharmaceuticals and agrochemicals. 6-NITRO-1,3-BENZODIOXOL-5-AMINE is a pale yellow crystalline substance that is insoluble in water but soluble in organic solvents. It is also known to be a potential mutagen and is classified as hazardous to aquatic environments. Due to its chemical properties and potential health and environmental risks, careful handling and disposal of this compound is necessary.

InChI:InChI=1/C7H6N2O4/c8-4-1-6-7(13-3-12-6)2-5(4)9(10)11/h1-2H,3,8H2

Upstream product

• 7748-59-6 5,6-dinitro-benzo[1,3]dioxole 
• 64-17-5 ethanol 
• 7748-57-4 5-chloro-6-nitro-benzo[1,3]dioxole 
• 7664-41-7 ammonia 
• 81864-14-4 N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 13067-19-1 3,4-methylenedioxyacetanilide 

Downstream Products

• 7107-10-0 4-hydroxy-5-nitro-1,2,methylenedioxybenzene 
• 93415-78-2 N-(2'-Carbomethoxy-6'-nitrophenyl)-5-amino-6-nitro-1,3-benzdioxol 
• 892123-42-1 C₁₆H₁₃N₃O₉ 
• 81864-15-5 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride 
• 7106-74-3 5-Iodo-6-nitrobenzo[d][1,3]dioxole 

Relevant articles and documents

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.